PAVmed Inc. Files 8-K on Security Holder Votes and Financials

TL;DR

PAVM filed an 8-K on 6/20/24 covering shareholder votes and financials.

AI Summary

On June 20, 2024, PAVmed Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing includes information about common stock and warrants to purchase common stock.

Why It Matters

This filing provides crucial updates for PAVmed Inc. shareholders regarding voting matters and financial performance, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating immediate operational or financial distress.

Key Players & Entities

• PAVmed Inc. (company) — Registrant
• June 20, 2024 (date) — Date of earliest event reported
• 001-37685 (other) — Commission File Number
• 47-1214177 (other) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 Per Share PAVM The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 50KB
• 0001493152-24-024540.txt ( ) — 263KB
• pavm-20240620.xsd (EX-101.SCH) — 4KB
• pavm-20240620_def.xml (EX-101.DEF) — 26KB
• pavm-20240620_lab.xml (EX-101.LAB) — 36KB
• pavm-20240620_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2024 PAVMED INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37685 47-1214177 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 360 Madison Avenue , 25th Floor , New York , New York 10017 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (917) 813-1828 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 Per Share PAVM The Nasdaq Stock Market LLC Series Z Warrants to Purchase Common Stock PAVMZ The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07. Submission of Matters to a Vote of Security Holders. On June 20, 2024, PAVmed Inc. (the " Company ") held an annual meeting of stockholders (the " 2024 Annual Meeting "). Stockholders representing approximately 58.5% of the shares outstanding and entitled to vote were present in person or by proxy. At the 2024 Annual Meeting, the stockholders elected each of management's nominees for director and approved the other matter considered. A description of the matters considered by the stockholders and a tally of the votes on each such matter are set forth below. 1. The election of two members of the Company's board of directors (the " Board ") as Class B directors, to hold office until the third succeeding annual meeting and until their respective successors are duly elected and qualified. The Board is divided into three classes, Class A, Class B and Class C. As of the 2024 Annual Meeting, there were two directors in Class B, James L. Cox, M.D. and Debra J. White, whose terms expired at the 2024 Annual Meeting, three directors in Class C, Lishan Aklog, M.D., Michael J. Glennon and Joan B. Harvey, whose terms expire at the 2025 annual meeting of stockholders, and two directors in Class A, Ronald M. Sparks and Timothy Baxter, whose terms expire at the 2026 Annual Meeting. The board nominated Dr. Cox and Ms. White for re-election as Class B directors. Each of the board's nominees for director was elected, as follows: Name For Authority Withheld Broker Non-Votes James L. Cox, M.D. 2,177,207 128,338 3,209,395 Debra J. White 2,234,311 71,234 3,209,395 2. A proposal to ratify the appointment of Marcum LLP as the Company's independent registered certified public accounting firm for the year ending December 31, 2024. The ratification of the appointment of Marcum LLP was approved, as follows: For Against Abstain Broker Non-Votes 5,378,887 92,448 43,605 — Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 20, 2024 PAVMED INC. By: /s/ Dennis McGrath Dennis McGrath President and Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR